22.04.2025 | Tracker
Top 50 Pharma Tracker: Ozempic approval, Super Bowl ad and Monday Night IBD all hits for HCPs
By Aman Jandu The Top 50 Pharmaceutical Companies mentioned by HCPs on X
| Current Quarter Rank | Previous Quarter Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 7,451 | 443 | 13 |
| 2 | 2 | Moderna | 3,499 | 150 | 1 |
| 3 | 3 | Johnson & Johnson | 1,622 | 409 | 0 |
| 4 | 6 | GSK | 1,074 | 196 | 8 |
| 5 | 8 | Lilly | 983 | 456 | 0 |
| 6 | 12 | Merck & Co | 963 | 246 | 11 |
| 7 | 7 | Novo Nordisk | 942 | 468 | 33 |
| 8 | 4 | AstraZeneca | 931 | 331 | 18 |
| 9 | 15 | Bayer | 858 | 185 | 6 |
| 10 | 10 | Roche | 587 | 165 | 16 |
| 11 | 14 | AbbVie | 475 | 368 | 58 |
| 12 | 9 | Sanofi | 419 | 145 | 6 |
| 13 | 13 | Abbott | 395 | 382 | 16 |
| 14 | 16 | Novartis | 366 | 216 | 5 |
| 15 | 5 | Novavax | 347 | 22 | 0 |
| 16 | 11 | Gilead Sciences | 328 | 76 | 9 |
| 17 | 19 | Takeda | 300 | 283 | 0 |
| 18 | 17 | Amgen | 242 | 121 | 3 |
| 19 | 21 | Otsuka | 198 | 16 | 0 |
| 20 | 23 | BMS | 144 | 101 | 6 |
| 21 | 20 | Daiichi Sankyo | 118 | 63 | 16 |
| 22 | 25 | Fresenius | 116 | 49 | 12 |
| 23 | 22 | Teva | 113 | 62 | 0 |
| 24 | 24 | Organon | 101 | 9 | 0 |
| 25 | 31 | Servier | 95 | 79 | 19 |
| 26 | 18 | Boehringer Ingelheim | 91 | 72 | 3 |
| 27 | 26 | Chugai | 72 | 4 | 4 |
| 28 | 27 | Regeneron | 70 | 39 | 7 |
| 29 | 29 | STADA Arneimittel | 69 | 0 | 0 |
| 30 | 28 | Astellas | 62 | 38 | 0 |
| 31 | 30 | UCB | 60 | 46 | 15 |
| 32 | 42 | Bausch | 57 | 8 | 4 |
| 33 | 35 | Biogen | 50 | 22 | 0 |
| 34 | 33 | Ipsen | 45 | 16 | 0 |
| 35 | 36 | Vertex | 32 | 29 | 1 |
| 36 | 37 | Menarini | 31 | 18 | 0 |
| 37 | 32 | Merck KGaA | 30 | 20 | 6 |
| 38 | 37 | Jazz Pharmaceuticals | 23 | 12 | 0 |
| 38 | 40 | Dr. Reddy's Labratories | 23 | 0 | 0 |
| 40 | 34 | Viatris | 22 | 3 | 0 |
| 41 | 39 | Eisai | 19 | 6 | 0 |
| 42 | 45 | Sun | 14 | 2 | 0 |
| 43 | 41 | Grifols | 9 | 0 | 0 |
| 43 | 44 | Incyte | 9 | 7 | 0 |
| 45 | 42 | CSL | 5 | 2 | 0 |
| 46 | 50 | Jiangsu Hengrui | 3 | 0 | 0 |
| 47 | 50 | Mitsubishi Chemical Group | 1 | 0 | 0 |
| 50 | 46 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Yunnan Baiyao Group | 0 | 0 | 0 |
2025 Q1’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five most mentioned pharmaceutical companies by HCPs on X between January and March 2025 were Pfizer, Moderna, Johnson & Johnson, GSK and Lilly.
CREATION.co tracked 20,558 mentions by 6,272 individual HCPs of pharmaceutical companies between January and March 2025.
Abbott supports HCPs in UK Parliament
On 28 January, HCPs gathered in the UK Parliament to discuss heart failure with MPs and the need for earlier detection and prevention. Cardiologist Carol Whelan shared her experience on X, thanking patients for attending and sharing their stories and also thanking Abbott for supporting the initiative. Her post was shared by 3 HCPs.
Great to be at @UKParliament today highlighting #heartfailure and @BSHeartFailure #25in25 campaign BSH Chair Lisa Anderson spoke of the need to detect heart failure earlier and to prevent it. Thanks to @AbbottNews for supporting, MPs and patients Ged and Bob for their stories pic.twitter.com/Nq74bv9vlt
— Carol Whelan (@CJWhelan18) January 28, 2025
Shared by 3 HCPs
FDA Approval of Ozempic for Kidney Failure
On 29 January, the Food and Drug Administration (FDA) approved Novo Nordisk’s Ozempic for the prevention of kidney failure in patients with type 2 diabetes who have chronic kidney disease. The news was well received by HCPs such as bariatric surgeon Neil Floch and obesity physician Michael Albert – ranked #2 and #5 globally in DOL Finder amongst the top most impactful HCPs in type 2 diabetes. Michael Albert called this approval “big news”, with physician Ted Kyle commenting that this “cements the leadership status of semaglutide”.
"Big news," says @MichaelAlbertMD and we agree. @NovoNordisk cements the leadership status of #semaglutide with @US_FDA approval of indication to prevent kidney failure and death in chronic #KidneyDisease and #diabetes. https://t.co/jA8iJRp5tT pic.twitter.com/Xnt1Y00hi6
— Ted Kyle (@ConscienHealth) January 29, 2025
Endocrinologist Daniel Drucker (ranked #1 in DOL Finder as the most impactful HCP in type 2 diabetes) weighed in on the conversation, highlighting that the trial was stopped early due to “clear benefits”. In his post, he tagged the Food and Drug Administration (FDA) and Novo Nordisk’s US account. The post was shared by 18 HCPs, marking a clear impact on his peers.
The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease @US_FDA @novonordiskus pic.twitter.com/CZzYde77T8
— Daniel J Drucker (@DanielJDrucker) January 28, 2025
Shared by 18 HCPs
Another Super Bowl Touchdown for Pfizer
On 09 February, HCPs took time to comment on Pfizer’s Super Bowl advert, showing support for their commitment to fight cancer. World-renowned sports announcer Michael Buffer shared his thoughts, showing thanks to Pfizer for their commitment. Paediatric nurse M. Elisabeth shared his post and also commented how “this Super Bowl spot gave me real goosebumps”.
Big thanks to Pfizer for their battle against cancer.
As a 16yr cancer survivor it’s an honor to be a part of this SuperBowl spot featuring the great LL Cool J’s legendary hit “Mama Said Knock You Out”
“LET’S GET READY TO RUMBLE!”®
Let’s KO cancer!🥊 https://t.co/S0VYlDu9PE— Michael Buffer (@Michael_Buffer) February 9, 2025
Well, Pfizer — this Super Bowl spot gave me real goosebumps.
https://t.co/s6XIw2QytI— M. Elisabeth (@ChildrenNeedUs_) February 10, 2025
Roche’s breakthrough in DNA sequencing
On 02 March, immunologist Derya Unutmaz shared a post highlighting a breakthrough from Roche based on DNA sequencing technology. Derya Unutmaz expressed his excitement for this, calling it “the most amazing DNA sequencing technology I’ve ever seen!” and then going on to say this technology is “truly impressive!”. The post was shared by 2 HCPs.
This is the most amazing DNA sequencing technology I’ve ever seen!
This groundbreaking innovation developed by @Roche could dramatically transform countless biomedical applications-from early disease & cancer detection to affordable, personalized treatments! Truly impressive!😲 pic.twitter.com/iE9RHnLqNS
— Derya Unutmaz, MD (@DeryaTR_) March 2, 2025
Shared by 2 HCPs
Monday Night IBD – 24 March
On 24 March, HCPs in the inflammatory bowel disease (IBD) space connected for a weekly online conversation between peers. Supported by Eli Lilly through educational grants, the conversations took place between gastroenterologist Aline Chatabaty and IBD clinical director Shrinivas Bishu (ranked #1 and #10, respectively, globally in DOL Finder for IBD). The discussion in this particular event was related to ulcerative colitis and what’s next for patients after treatment with TNFi drugs.
📣Join us now for a convo led by @IBDimmunology @DCharabaty
With 🆕MOAs in our 🧰
What’s next for #ulcerativecolitis after TNFi ?
How do you ⚖️ efficacy/ safety/ comorbidities / age?
🗳️IBDPoll👇🏽
💬Share your thoughtsSupported by educational grant @EliLillyandCo pic.twitter.com/XZ4qnOGfvo
— #MondayNightIBD (@MondayNightIBD) March 24, 2025
Shared by 13 HCPs
Monday Night IBD is a well-received initiative amongst peers within the gastroenterology community, which poses the question: What other online initiatives could pharmaceutical companies support to grow a thriving community of HCPs online?
Should pharmaceutical companies listen to online HCPs?
Over the last quarter, HCPs celebrated online when pharmaceutical companies reached endpoints to cancer treatment trials, supported initiatives to address the disparity in clinical trial diversity and worked on treatment options that provide more options to patients.
The top shared links by HCPs when mentioning a Top 50 pharma company discussed:
- A satirical article from the Babylon Bee about RFK Jr’s questioning at the Senate.
- A SciTechDaily article highlighting a discovery of spike proteins in the brain linked to Long COVID.
- A blog post relating to Merck’s safety testing for Gardasil.
It’s clear that many HCPs rely on social media to discover and share new medical science. As well as being amplifiers and disseminators of new science, their collective and individual voices provide a powerful guide to how physicians think new treatments will shape patient care now and in the future.
By listening to the online voice of healthcare professionals, medicine manufacturers can discover what’s important to physicians on the front lines of patient care, find out whether their messaging about new medicines is resonating, and predict future HCP behaviours.
At CREATION.co, we’ve been tracking the online HCP voice for over a decade, thanks to our specialist technology platform, CREATION Pinpoint. Talk with us about how our insights can inspire your next innovation.
——
Find out how the conversation is changing in other Top 50 Trackers and new analysis of the online HCP conversation in a variety of topics.
You can also receive these updates and more straight to your inbox by signing up to CREATION.co’s monthly eJournal.
Methodology notes:
- In January – March 2025, CREATION Pinpoint® identified 20,258 posts on X (Twitter) from 6,272 individual HCPs mentioning a Top 50 Pharmaceutical company (based on revenue).
- Data for this research was analysed from the online X conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 January – 31 March 2025.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In January – March 2025, 86 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.
